Skip to content

Environmental Mixtures, Cognitive Control and Reward Processes, and Risk for Psychiatric Problems in Adolescence

Environmental Mixtures, Cognitive Control and Reward Processes, and Risk for Psychiatric Problems in Adolescence

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05795452
Enrollment
250
Registered
2023-04-03
Start date
2022-02-20
Completion date
2026-05-01
Last updated
2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatric Problem

Keywords

Functional magnetic resonance imaging (fMRI), Cognitive function, Cognitive Control, Reward Processing

Brief summary

This study aims to examine the cognitive and neural pathways underlying the joint impact of chemical and social exposures on two aspects of cognitive function: cognitive control and reward processing. The investigators will use high resolution, multi-band resting state and task functional magnetic resonance imaging (fMRI) as well as neuromelanin stain MRI to identify pathways through which exposure to a mixture of prenatal chemical and early life social exposures alters brain function and behavior. Specifically, the investigators will leverage extant prenatal exposure data (N=550) from the Columbia Center for Children's Environmental Health (CCCEH) Mothers and Newborns (MN) birth cohort and study symptoms and brain function in adolescence.

Detailed description

Adolescence is a period of high risk for the emergence of psychiatric issues, particularly attention problems, substance abuse, and psychotic experiences. Risk for these problems likely originates in the prenatal period when the brain undergoes significant rapid change, making this a particularly vulnerable time for alterations in brain development. Few studies have examined risk from prenatal exposure to neurotoxicants that emerge in adolescence and the biological pathways that underlie these associations. Emerging findings suggest that prenatal exposure to environmental chemicals (e.g. environmental tobacco smoke (ETS), air pollutants such as polycyclic aromatic hydrocarbons (PAH)) is associated with behavioral symptoms of attentiondeficit/ hyperactivity disorder (ADHD), substance use disorders (SUD), and psychotic disorders (PD). These symptoms often emerge across adolescence, and frequently co-occur, suggesting shared underlying causes in the brain. Prenatal chemical exposures often co-occur with each other and with social exposures, such as early life stress (ELS) that are also associated with elevated behavioral symptoms. The joint contributions of these chemical and social exposures to these behavioral symptoms are understudied, as are the cognitive and neural pathways linking exposure to behavior.

Interventions

None listed

Sponsors

Ohio State University
Lead SponsorOTHER
National Institute of Environmental Health Sciences (NIEHS)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
13 Years to 20 Years
Healthy volunteers
No

Inclusion criteria

* Adolescents between 13-20 years * Available prenatal exposure data * Adolescents and parents are English- or Spanish-speaking

Exclusion criteria

* Presence of metallic device or dental braces * Full Scale Intelligence Quotient (IQ) \< 70 at prior assessment * Pregnant women or lactating women

Design outcomes

Primary

MeasureTime frameDescription
Youth Self Report (YSR) from the Child Behavior Checklist (CBCL)15 minutes during study visitThis is a 112-question scale for adolescents about their own behavioral functioning. It has a Likert-like scoring format and multiple syndrome and DSM-oriented scales, with higher scores indicating more symptoms. Raw scores are converted to T scores with a mean of 50 and standard deviation of 10. The range is 0 to 90.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAmy Margolis, PhD

Ohio State University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026